HTAC recommendation on Moderna COVID-19 Vaccine for children 6 to 11 years old
(Update as of 25 January 2023) On 31 August 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC)’s non-recommendation of additional procurement of Moderna for the implementation of the current primary vaccination series for children aged 6 to 11 years old because of its higher cost relative to a similar product in the market. However, existing continue reading : HTAC recommendation on Moderna COVID-19 Vaccine for children 6 to 11 years old
Evidence Summary on AstraZeneca COVID-19 vaccine as Second Booster/ Fourth Dose for the prevention of COVID-19
HTAC Recommendation on AstraZeneca COVID-19 vaccine as Second Booster/ Fourth Dose for the prevention of COVID-19 Date of OIC-SOH Approval: 14 November 2022 This assessment followed the HTAC evaluation framework to evaluate COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability, viability and feasibility; (4) household continue reading : Evidence Summary on AstraZeneca COVID-19 vaccine as Second Booster/ Fourth Dose for the prevention of COVID-19
DOST Visit to the HTA Philippines Office
The transition team from the Department of Science and Technology (DOST) went to the Health Technology Assessment (HTA) Philippines office under the Department of Health (DOH) on 13 January 2023 to discuss status updates and align on the next steps, in parallel with the ocular inspection of facilities to prepare for the anticipated physical reporting continue reading : DOST Visit to the HTA Philippines Office